Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Anatomic Site Laterality Code	NCIT_C93505	[A coded value specifying the side of the body (or a paired organ) where the anatomic site is.]
Iodine I 124 Phospholipid Ether Analogue CLR1404	NCIT_C107500	[A small molecule radiopharmaceutical composed of the radioisotope iodine I 124 covalently attached to a proprietary alkylphospholipid ether (PLE) analogue, with potential imaging activity upon positron emission tomography (PET). Iodine I 124 phospholipid ether analogue CLR1404 is selectively taken up by tumor cells via membrane lipid rafts and accumulates in tumor cells. The accummulation of this agent is due to a decreased ability of tumor cells to metabolize PLEs because certain tumor cells have lower levels of the enzyme phospholipase-D, in comparison to normal cells. This facilitates imaging of cancer cells by PET. Lipid rafts, specialized microdomains of plasma membrane, are overexpressed in cancer cells compared to normal cells. In addition, the radioiodine moiety of this agent is resistant to de-iodination.]
Aloe/Anise/Ascorbic Acid/Clove/Peppermint/Spearmint/Thyme-based Mouthwash	NCIT_C107501	[A herbal-based mouthrinse containing aloe, anise, ascorbic acid, clove, peppermint, spearmint and thyme, with potential anti-mucositic activity. When aloe/anise/ascorbic acid/clove/peppermint/spearmint/thyme-based mouthwash is used as a rinse, the ingredients in this agent may prevent or decrease inflammation and bacterial infections.This may prevent or inhibit radiotherapy- or chemotherapy-induced mucositis and decreases the pain associated with mucositis.]
Glioblastoma Cancer Vaccine ERC1671	NCIT_C107502	[A cancer vaccine composed of a combination of autologous glioblastoma (GBM) tumor cells, allogeneic GBM tumor cells, generated from three different GBM donor cancer patients, and the lysates of all of these cells, with potential antineoplastic activity. Upon intradermal administration of GBM cancer vaccine ERC1671, the mixture of the autologous and allogeneic cells and lysates stimulates the immune system to mount a cytotoxic T-lymphocyte (CTL) response against GBM-associated antigens, which leads to the destruction of glioblastoma cells.]
Superagonist Interleukin-15:Interleukin-15 Receptor alphaSu/Fc Fusion Complex ALT-803	NCIT_C107503	[A fusion protein complex composed of a mutated form of the cytokine interleukin (IL)-15 (IL-15N72D) and a soluble, dimeric IL-15 receptor alpha (IL-15Ra) Fc fusion protein (IL-15Ra-Fc) (IL-15N72D/IL-15Ra-Fc), with potential antineoplastic activity. Upon administration, superagonist interleukin-15:interleukin-15 receptor alphaSu/Fc fusion complex ALT-803 binds to the IL-2/IL-15 receptor beta-common gamma chain (IL-2Rbetagamma) receptor on natural killer (NK) and CD8+ T lymphocytes, which activates and increases the levels of NK cells and memory CD8+(CD44high) T-cells. The memory T-cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. This may increase tumor cell killing and decrease tumor cell proliferation. IL-15 regulates CD8+ T and NK cell development, activation and proliferation. By coupling IL-15 to IL15Ra-Fc, this agent has a prolonged drug half-life and shows an increased ability to bind IL-2Rbetagamma, which enhances its immune stimulatory activity as compared to IL-15 alone.]
Recombinant Human Adenovirus Type 5 H101	NCIT_C107504	[A replication selective, recombinant, E1B and partial E3 gene deleted form of human adenovirus type 5, with potential antineoplastic activity. Upon intratumoral injection of recombinant human adenovirus type 5, the adenovirus selectively replicates in cancer cells while preventing viral replication in normal, healthy cells. This induces a selective adenovirus-mediated cytotoxicity in cancer cells, which leads to cancer cell lysis. In addition, viral spread to adjacent cells, following lysis of infected cells, may activate the immune system to kill the infected tumor cells. The E1B protein causes p53 inactivation, which promotes viral replication; deletion of E1B allows for p53 activation in normal cells, which prevents viral replication in normal, healthy cells. The mutation and subsequent inactivation of p53 in cancer cells enables the E1B-deleted adenovirus to selectively replicate in cancer cells. Partial deletion of E3, encoding the adenovirus death protein, enhances the safety profile of the administered adenovirus.]
CD138CAR-CD137/TCRzeta-expressing T Lymphocytes	NCIT_C107505	[T-lymphocytes transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) specific for syndecan-1 (CD138) (CART-138 T cells) coupled to the signaling domain of 4-1BB (CD137), and the zeta chain of the T-cell receptor (TCRzeta), with potential immunomodulating and antineoplastic activities. Upon transfusion, CD138CAR- CD137/TCRzeta -expressing T lymphocytes directs the T-lymphocytes to syndecan-1-expressing tumor cells and induces selective toxicity in those tumor cells. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of syndecan-1. Syndecan-1, a type 1 transmembrane proteoglycan and tumor associated antigen, is overexpressed in a variety of cancer cells. It plays a key role in the regulation of cell growth, differentiation, and adhesion, and its expression is correlated with poor prognosis.]
Tazemetostat	NCIT_C107506	[An orally available, small molecule selective and S-adenosyl methionine (SAM) competitive inhibitor of histone methyl transferase EZH2, with potential antineoplastic activity. Upon oral administration, tazemetostat selectively inhibits the activity of both wild-type and mutated forms of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased tumor cell proliferation in EZH2 mutated cancer cells. EZH2, which belongs to the class of histone methyltransferases (HMTs), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation.]
Allyl Isothiocyanate	NCIT_C68556
Isothiocyanate	NCIT_C45711	[A chemical group containing the monovalent -N=C=S group. Isothiocyanate is the fundamental structure in many synthetic and biological active compounds.]
Multinational Association of Supportive Care in Cancer Antiemesis Tool	NCIT_C107507	[A self-administered questionnaire designed to assess a patient's level of nausea and vomiting associated with chemotherapy.]
CHD5 Gene	NCIT_C68557	[This gene is involved in both chromatin structure regulation and tumor suppression.]
Baseline Nausea and Vomiting	NCIT_C107508	[A set of parameters established as a reference to gauge levels of nausea and vomiting.]
Baseline	NCIT_C25213	[A starting point to which things may be compared.]
CHD5 wt Allele	NCIT_C68558	[Human CHD5 wild-type allele is located in the vicinity of 1p36.3 and is approximately 78 kb in length. This allele, which encodes chromodomain-helicase-DNA-binding protein 5, is involved in chromatin remodeling and transcriptional regulation. Depletion of the wild-type allele contributes to the pathogenesis of several cancers; including: neural cancers, melanoma, hematopoietic cancers and several epithelial cancers.]
1p36.3	NCIT_C13527	[A chromosome band present on 1p]
Vomiting in the Last 24 Hours	NCIT_C107509	[A question about whether an individual vomited in the last 24 hours.]
Chromodomain-Helicase-DNA-Binding Protein 5	NCIT_C68559	[Chromodomain-helicase-DNA-binding protein 5 (1954 aa, ~223 kDa) is encoded by the human CHD5 gene. This protein may play a role in neural system development and in neural tumor pathogenesis.]
N-Telopeptide	NCIT_C68563	[This polypeptide is comprised of the amino terminal portions of fibrillar collagen, which are not part of the triple helical structure. Bone resorption of type I collagen by osteoclasts results in the release of this peptide. Thus, this polypeptide is utilized as a biomarker for bone loss.]
Type I Collagen	NCIT_C124129	[A heterotrimeric fibrillar protein complex comprised of two collagen alpha-1(I) chains and one collagen alpha-2(I) chains. Type I collagen is the most abundant fibrillar collagen in humans and is present in scar tissue, tendons, ligaments, bone, dermis, dentin, and organ capsules.]